Pharmaids Pharma Peer Comparison

BSE: 524572

₹31.98

₹-0.31 (-0.96%)

As on 28-Aug-2026IST

Market cap

₹113 Cr

Revenue (TTM)

₹25 Cr

P/E Ratio

--

P/B Ratio

2.3

Div. Yield

0 %

Edit

	Pharmaids Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Market cap (₹ Cr)	113	32,104	29,892	29,103	26,871
Revenue (₹ Cr)	25	3,564	1,936	9,205	1,462
Net Profit (₹ Cr)	-4.39	414.00	288.22	-371.81	387.35
Net Margin (%)	-17.02	11.23	14.79	-3.93	26.01
RoE (%)	-20.22	8.38	29.77	-3.85	25.18
Price to Earnings	--	78.49	103.71	--	69.57
Price-To-Book	2.28	6.38	22.27	3.64	15.55

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Pharmaids Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Operating Revenue	27.88	3,373.00	1,753.96	8,869.08	1,006.88
Total Income	28.17	3,510.00	1,762.66	9,111.51	1,023.80
Total Expenditure	41.39	2,747.00	1,354.69	7,976.59	774.80
EBITDA	-13.51	626.00	399.26	892.49	232.07
Depreciation	2.03	227.00	45.26	831.24	26.62
EBIT	-15.54	399.00	354.00	61.25	205.45
Interest	3.52	213.00	42.17	340.80	6.22
Other Income	0.29	137.00	8.70	242.43	16.93
Exceptional Items	2.46	-85.00	--	-196.14	--
Profit before Tax	-16.30	238.00	320.53	-176.06	216.16
Provision for Tax	-4.73	39.00	73.80	149.88	55.75
Profit after Tax	-11.57	199.00	246.74	-325.94	160.42

Liabilities (₹ Cr)

	Pharmaids Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Shareholder's Funds	47.65	4,940.00	1,288.82	8,162.62	1,309.63
Minority Interest	-0.05	341.00	0.00	--	10.45
Non-Current Liabilities	3.37	1,235.00	189.02	4,529.41	26.93
Current Liabilities	24.01	1,622.00	835.87	4,874.74	202.25
Total Liabilities	87.26	8,578.00	2,326.71	17,723.32	1,549.26

Assets (₹ Cr)

	Pharmaids Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Non-Current Assets	63.99	5,441.00	631.90	10,258.66	757.63
Current Assets	10.99	2,606.00	1,681.81	7,308.11	791.64
Total Assets	87.26	8,578.00	2,326.71	17,723.32	1,549.26
Total Debt*	20.91	2,125.00	259.37	5,495.48	8.18
Net Current Assets	-13.02	984.00	845.94	2,433.37	589.39
Contingent Liabilities	--	768.26	19.09	95.72	15.38

Cashflow (₹ Cr)

	Pharmaids Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Cash From Operating Activities	-4.06	390.00	205.05	1,652.60	118.34
Cash Flow from Investing Activities	23.34	-241.00	-409.72	-826.03	-223.94
Cash from Financing Activities	-19.97	-54.00	283.07	-38.98	261.12
Net Cash Inflow / Outflow	-0.69	95.00	78.39	787.59	155.52

Ratios

Profitability Ratios

	Pharmaids Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
ROCE (%)	-15.67	6.79	29.22	1.24	20.14
ROE (%)	-21.64	4.29	27.84	-4.04	16.19
ROA (%)	-12.56	2.53	13.11	-1.98	12.13
EBIT Margin (%)	-47.42	22.62	23.26	12.80	24.73
Net Margin (%)	-41.08	5.67	14.00	-3.58	15.67
Cash Profit Margin (%)	-34.23	10.98	7.71	4.80	18.58

Growth Ratios

	Pharmaids Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Revenue Growth (%)	43.37	11.99	36.57	-3.08	40.34
EBIT Growth (%)	-4.60	67.69	52.29	-28.15	83.12
Net Profit Growth (%)	14.31	449.12	83.64	-457.66	229.35
EPS Growth (%)	-8.73	553.20	71.44	-456.91	67.16
Book Value Growth (%)	-19.67	13.47	144.31	0.33	94.96

Valuation Ratios

	Pharmaids Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Price / Earnings	0.00	89.54	51.69	0.00	62.97
Price / Book Value	2.05	3.87	10.14	2.24	15.26
Dividend Yield (%)	0.00	0.00	0.19	0.00	0.06
EV/EBITDA	-8.95	27.45	31.05	19.72	79.31
Market Cap (₹ Cr)	97.59	19,071.62	12,753.19	18,108.89	19,988.69

Solvency Ratios

	Pharmaids Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debt to Equity	0.44	0.43	0.21	0.68	0.01
Short term debt to equity ratio	0.19	0.09	0.05	0.09	0.01
Current Ratio	0.46	1.61	2.01	1.50	3.91
Quick Ratio	0.44	1.06	1.14	0.87	3.02
Interest Coverage	-3.63	2.12	8.60	0.48	35.76

Operating Efficiency Ratios

	Pharmaids Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debtors to sales (%)	12.30	17.43	29.00	24.33	28.85
Asset Turnover	0.30	0.49	2.01	0.64	0.76
Receivable days	42.92	58.75	40.13	78.20	90.06
Inventory Days	82.44	75.82	60.29	93.30	61.02
Payable days	203.23	186.21	232.47	226.14	96.06
Cash Conversion Cycle	-77.87	-51.64	-132.04	-54.64	55.02

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.